What is the recommended insulin management for a patient with diabetes taking Lantus (insulin glargine) 20 units and a sliding scale, undergoing an esophagogastroduodenoscopy (EGD) and colonoscopy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Perioperative Insulin Management for EGD and Colonoscopy

Recommended Approach

On the morning of the procedure, administer 70-80% of the patient's usual Lantus dose (14-16 units) and completely discontinue the sliding scale insulin regimen, replacing it with a structured basal-bolus approach postoperatively. 1

Day of Procedure Protocol

Morning Insulin Dosing

  • Give 14-16 units of Lantus (70-80% of usual 20 units) on the morning of the procedure 1
  • This 20-25% reduction prevents hypoglycemia during the fasting period while maintaining basal coverage 1
  • Administer at the patient's usual time if possible 1

Monitoring Requirements

  • Check fasting blood glucose before the procedure 1
  • Monitor glucose every 2-4 hours during the perioperative period 2
  • Have glucose tablets or IV dextrose immediately available for hypoglycemia treatment 2

Critical Problems with Current Regimen

Sliding scale insulin as monotherapy is explicitly condemned by all major diabetes guidelines and should be immediately discontinued. 1 The current regimen of Lantus plus sliding scale represents inadequate diabetes management for several reasons:

  • Sliding scale insulin treats hyperglycemia reactively after it occurs rather than preventing it 1
  • This approach leads to dangerous glucose fluctuations and poor glycemic control 1
  • Scheduled basal-bolus regimens are superior to sliding scale monotherapy 1

Post-Procedure Insulin Regimen

Resume Full Basal Insulin

  • Return to Lantus 20 units once daily after the patient resumes oral intake 1
  • Continue at the same time each day for consistency 1

Add Structured Prandial Coverage

The patient requires prandial insulin in addition to basal insulin, not sliding scale monotherapy. 1 Based on the inadequacy of the current regimen:

  • Start with 4 units of rapid-acting insulin (lispro, aspart, or glulisine) before the largest meal 1
  • Alternatively, use 10% of the basal dose (2 units) before each meal 1
  • Titrate prandial doses by 1-2 units every 3 days based on 2-hour postprandial glucose readings 1

Correction Insulin (Not Sliding Scale)

  • Use correction doses as an adjunct to scheduled insulin, not as monotherapy 1
  • Calculate insulin sensitivity factor: 1500 ÷ total daily dose 1
  • Apply correction doses only when blood glucose exceeds target before meals 1

Foundation Therapy Considerations

Continue Metformin

  • Metformin should be continued unless contraindicated, even when intensifying insulin therapy 1
  • Metformin may be temporarily held 24-48 hours before the procedure if there are concerns about renal function or contrast administration 2
  • Resume metformin after the procedure once oral intake is established and renal function is stable 2

Hypoglycemia Prevention and Treatment

Recognition and Treatment Protocol

  • Treat hypoglycemia at blood glucose ≤70 mg/dL with 15 grams of fast-acting carbohydrate 1
  • Recheck glucose in 15 minutes and repeat treatment if needed 2
  • Staff should have glucagon available for severe hypoglycemia 2

Risk Mitigation

  • The reduced Lantus dose (70-80%) on procedure day specifically addresses hypoglycemia risk during fasting 1
  • If hypoglycemia occurs, reduce the next Lantus dose by 10-20% 1

Common Pitfalls to Avoid

Do Not Continue Sliding Scale Monotherapy

  • Sliding scale as sole treatment is ineffective and dangerous 1
  • Scheduled basal insulin with correction doses as adjunct only is superior 1

Do Not Delay Prandial Insulin Addition

  • The current regimen suggests inadequate glycemic control requiring both basal and prandial coverage 1
  • Continuing to rely on sliding scale without structured prandial insulin leads to suboptimal control 1

Do Not Omit All Insulin on Procedure Day

  • Complete insulin omission risks hyperglycemia and metabolic decompensation 1
  • Reduced basal insulin (70-80%) maintains coverage while preventing hypoglycemia 1

Monitoring and Follow-Up

Immediate Post-Procedure Period

  • Monitor glucose every 2-4 hours until stable oral intake is established 2
  • Adjust insulin doses by 10-20% if hypoglycemia occurs 1

Long-Term Management

  • Daily fasting blood glucose monitoring is essential during titration 1
  • Check pre-meal and 2-hour postprandial glucose to guide prandial insulin adjustments 1
  • Reassess every 3-6 months with HbA1c monitoring 1

References

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.